Clinical trial NCT00679679 - References

Polycystic Ovary Syndrome — Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome

Citation(s)

•   Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group
  The metabolic syndrome--a new worldwide definition. Lancet. 2005 Sep 24-30;366(9491):1059-62.
•   Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF
  A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000 Jul;85(7):2434-8.
•   Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'Keefe M, Ghazzi MN; PCOS/Troglitazone Study Group
  Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001 Apr;86(4):1626-32.
•   Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO
  The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004 Jun;89(6):2745-9.
•   Bahceci M, Bilge M, Tuzcu A, Tuzcu S, Bahceci S
  Serum prostate specific antigen levels in women with polycystic ovary syndrome and the effect of flutamide+desogestrel/ethinyl estradiol combination. J Endocrinol Invest. 2004 Apr;27(4):353-6.
•   Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ
  Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab. 1986 May;62(5):904-10.
•   Cassidenti DL, Paulson RJ, Serafini P, Stanczyk FZ, Lobo RA
  Effects of sex steroids on skin 5 alpha-reductase activity in vitro. Obstet Gynecol. 1991 Jul;78(1):103-7.
•   Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF 2nd, Fitzpatrick LA
  Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003 Jun;88(6):2562-8.
•   Clements J, Mukhtar A
  Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab. 1994 Jun;78(6):1536-9.
•   Dahlgren E, Janson PO, Johansson S, Lapidus L, Odén A
  Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand. 1992 Dec;71(8):599-604.
•   Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI
  A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999 Nov;84(11):4006-11.
•   Dunaif A, Segal KR, Futterweit W, Dobrjansky A
  Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989 Sep;38(9):1165-74.
•   Dunaif A
  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997 Dec;18(6):774-800. Review.
•   Ehrmann DA
  Polycystic ovary syndrome. N Engl J Med. 2005 Mar 24;352(12):1223-36. Review.
•   Escobar-Morreale HF, Avila S, Sancho J
  Serum prostate-specific antigen concentrations are not useful for monitoring the treatment of hirsutism with oral contraceptive pills. J Clin Endocrinol Metab. 2000 Jul;85(7):2488-92.
•   Escobar-Morreale HF, Serrano-Gotarredona J, Avila S, Villar-Palasí J, Varela C, Sancho J
  The increased circulating prostate-specific antigen concentrations in women with hirsutism do not respond to acute changes in adrenal or ovarian function. J Clin Endocrinol Metab. 1998 Jul;83(7):2580-4.
•   Güllü S, Emral R, Asik M, Cesur M, Tonyukuk V
  Diagnostic value of prostatic specific antigen in hirsute women. J Endocrinol Invest. 2003 Dec;26(12):1198-202.
•   Guzelmeric K, Seker N, Unal O, Turan C
  High serum prostate-specific antigen concentrations in hirsute women do not decrease with treatment by the combination of spironolactone and the contraceptive pill. Gynecol Endocrinol. 2004 Oct;19(4):190-5.
•   Harborne L, Fleming R, Lyall H, Norman J, Sattar N
  Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet. 2003 May 31;361(9372):1894-901. Review.
•   Kuhl H
  Comparative pharmacology of newer progestogens. Drugs. 1996 Feb;51(2):188-215. Review.
•   Legro RS, Kunselman AR, Dodson WC, Dunaif A
  Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999 Jan;84(1):165-9.
•   Lord JM, Flight IH, Norman RJ
  Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev. 2003;(3):CD003053. Review. Update in: Cochrane Database Syst Rev. 2009;(3):CD003053.
•   Lord JM, Flight IH, Norman RJ
  Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003 Oct 25;327(7421):951-3. Review.
•   Matthaei S, Stumvoll M, Kellerer M, Häring HU
  Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev. 2000 Dec;21(6):585-618. Review.
•   Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS
  Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab. 2003 Jan;88(1):148-56.
•   Negri C, Tosi F, Dorizzi R, Fortunato A, Spiazzi GG, Muggeo M, Castello R, Moghetti P
  Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women. J Clin Endocrinol Metab. 2000 Jan;85(1):81-4.
•   Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG
  A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991 Jan;72(1):83-9.
•   Norman RJ, Homan G, Moran L, Noakes M
  Lifestyle choices, diet, and insulin sensitizers in polycystic ovary syndrome. Endocrine. 2006 Aug;30(1):35-43. Review.
•   Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD
  Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation. 2001 Mar 13;103(10):1410-5.
•   Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H
  Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007 Feb;92(2):405-13. Epub 2006 Nov 7.
•   Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group
  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004 Jan;19(1):41-7. Review.
•   Sam S, Dunaif A
  Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab. 2003 Oct;14(8):365-70. Review.
•   Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T, Engberg RA
  Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol. 1998 May;51(5):415-22.
•   Tepper SL, Jagirdar J, Heath D, Geller SA
  Homology between the female paraurethral (Skene's) glands and the prostate. Immunohistochemical demonstration. Arch Pathol Lab Med. 1984 May;108(5):423-5.
•   Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ
  Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994 May;43(5):647-54.
•   Wild RA
  Long-term health consequences of PCOS. Hum Reprod Update. 2002 May-Jun;8(3):231-41. Review.
•   Zarghami N, Grass L, Sauter ER, Diamandis EP
  Prostate-specific antigen in serum during the menstrual cycle. Clin Chem. 1997 Oct;43(10):1862-7.

Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial

Details for clinical trial NCT00679679